Inflation Reduction Act's out-of-pocket cap lowered insulin costs, improved usage for some patients

The Inflation Reduction Act's attempt to improve insulin costs for Medicare beneficiaries—by capping out-of-pocket costs at $35—was associated with lower out-of-pocket costs and increased insulin use, but only for a small portion of U.S. patients, according to a new study published in JAMA. ...